Results 241 to 250 of about 364,671 (298)
Esketamine and ketamine are widely used for perioperative analgesia and anesthesia. Despite their established roles in analgesia, sedation, and anesthesia, as well as emerging antidepressant, anti‐tumor, and anti‐inflammatory effects, their clinical use is limited due to side effects and addiction potential.
Yinxin Wang +7 more
wiley +1 more source
When Hyperthyroidism Slows the Heart: Graves' Disease Complicated by a High-Grade Atrioventricular Block. [PDF]
Ramdath MM, Teelucksingh JD.
europepmc +1 more source
In vivo optical imaging enhances antibody‐drug conjugate (ADC) optimization by enabling real‐time monitoring of stimulus‐responsive drug behavior. We report n501‐CYMMAF, a ratiometric theranostic with strong target affinity and low‐dose efficacy for ovarian metastasis.
Cheng Li +8 more
wiley +1 more source
Initial Treatment of Pediatric Graves' Disease with Methimazole: A Retrospective Follow-up Study
Rie Matsushita +11 more
openalex +2 more sources
A flexible piezoresistive sensor with a 3D tri‐scale graded microstructure is proposed, overcoming the trade‐off between sensitivity and linearity. The device achieves ultra‐high sensitivity (138.6 kPa−1), a broad linear range (400 kPa, R2 = 0.99), and exceptional stability (24 000 repeated loading cycles), enabling precise detection of physiological ...
Rui Chen +6 more
wiley +1 more source
Preoperative serum lipids as novel predictors for concomitant thyroid carcinoma in Graves' disease. [PDF]
Gao X, Liu M, Wu Y.
europepmc +1 more source
The advent of aptamers has highlighted their potential as alternatives to antibodies, overcoming limitations of structural instability and production cost. However, conventional approaches such as SELEX remain slow and labor‐intensive. This review examines recent advances in aptamer engineering, emphasizing in vitro and AI‐driven in silico strategies ...
John V. L. Nguyen +5 more
wiley +1 more source
Remission of Graves' Disease Through Lifestyle Interventions. [PDF]
Sharma P.
europepmc +1 more source

